How should fetal hydrops of unknown etiology be evaluated and managed?

Fetal Hydrops Without Etiology: Evaluation and Management

When fetal hydrops is diagnosed without an obvious cause, you must perform a systematic diagnostic workup starting with detailed ultrasound including fetal echocardiogram, followed by middle cerebral artery (MCA) Doppler to assess for anemia, then proceed to genetic testing with chromosomal microarray analysis (CMA) and/or karyotype, infectious workup, and consider lysosomal storage disease testing in structurally normal fetuses. 1

Initial Diagnostic Approach

Step 1: Comprehensive Ultrasound Evaluation

Begin with a detailed anatomic survey that includes:

• Fetal echocardiogram - cardiac anomalies are among the most common causes of non-immune hydrops fetalis (NIHF), accounting for 20-28% of cases 1, 2
• Survey of fetus, umbilical cord, and placenta for structural anomalies
• Assessment of amniotic fluid volume
• Identification of which body cavities are affected

Step 2: Rule Out Alloimmunization

Even though the question implies non-immune hydrops, confirm this by:

• Reviewing maternal blood type and Rh(D) status
• Checking indirect Coombs test (antibody screen)
• If previously normal, repeat the test 1

Step 3: Middle Cerebral Artery Doppler - Critical Decision Point

Perform MCA Doppler studies immediately - this is the key branch point in your diagnostic algorithm 1, 2:

If MCA PSV >1.5 MoM (Anemic):

• Proceed to fetal blood sampling if intrauterine transfusion is planned
• This allows direct measurement of fetal hematocrit/hemoglobin
• Obtain karyotype
• PCR testing for CMV, parvovirus, toxoplasmosis
• DNA testing for alpha-thalassemia if parental MCV <80 fL
• Consider G6PD deficiency, pyruvate kinase deficiency testing 1

Important: Fetal anemia from fetomaternal hemorrhage or parvovirus is treatable with intrauterine transfusion, which significantly improves outcomes. We recommend fetal intrauterine transfusion for NIHF due to parvovirus infection or fetomaternal hemorrhage, unless the pregnancy is at advanced gestational age where delivery risks are lower than procedural risks 1.

If MCA PSV Normal (Non-anemic):

Proceed with amniocentesis for:

• Karyotype and/or chromosomal microarray analysis (CMA) - should be offered regardless of whether structural anomalies are present 1, 3
• Amniotic fluid alpha-fetoprotein (AFAFP)
• PCR for infections if clinically indicated
• Lysosomal enzyme testing - particularly important as these account for 5.2% of all NIHF cases and 29.6% of idiopathic NIHF cases when comprehensive workup is performed 1

Maternal Laboratory Workup

Obtain the following maternal studies 1:

• Complete blood count with differential and indices
• Kleihauer-Betke stain for fetal hemoglobin (to detect fetomaternal hemorrhage)
• Parvovirus B19 serology - parvovirus is the most common infectious cause
• Syphilis serology (review or repeat)
• Consider acute phase titers for CMV and toxoplasmosis
• Parental mean corpuscular volume (MCV) - if <80 fL, suggests thalassemia carrier status 1

Advanced Genetic Testing

We recommend that exome or genome sequencing be offered in pregnancies with NIHF following CMA or karyotype that does not yield a diagnosis and in the absence of another suspected etiology 3. This is particularly important because:

• Genetic disorders account for approximately one-third of NIHF cases 1
• Chromosomal abnormalities (especially Turner syndrome and trisomy 21) account for 13% of cases 1
• Some genetic causes carry recurrence risks as high as 25% 1

Family History - Critical Component

Obtain a detailed family history focusing on 1:

• Known inherited disorders
• Consanguinity - increases likelihood of recessive disorders
• Previous pregnancy losses or hydrops
• Ethnic background (alpha-thalassemia is common in Southeast Asian populations, accounting for 28-55% of NIHF in these groups) 1

Common Pitfalls to Avoid

1. Don't skip the MCA Doppler - this is your critical decision point that determines the entire diagnostic pathway and identifies treatable anemia 2

2. Don't forget lysosomal storage diseases - these are often missed but account for nearly 30% of "idiopathic" cases when properly tested 1

3. Don't delay genetic testing - offer CMA/karyotype early, even in structurally normal fetuses, as aneuploidy can present without obvious anomalies 1, 3

4. Don't overlook parental testing - checking parental MCV for thalassemia carrier status is simple and can provide rapid diagnosis 1

Management Considerations

Fetal Intervention

Fetal intervention is associated with significantly lower perinatal mortality (OR 0.30,95% CI 0.14-0.61) 4. Consider intervention for:

• Fetal anemia (intrauterine transfusion)
• Pleural effusions (pleuroamniotic shunts)
• Cardiac arrhythmias (antiarrhythmic therapy for tachyarrhythmias)
• Large thoracic masses (fetal surgery in select cases)

Maternal Monitoring

Monitor for mirror syndrome - an uncommon but serious maternal complication where the mother develops edema "mirroring" the hydropic fetus 1. This presents with:

• Edema (~90% of cases)
• Hypertension (~60%)
• Proteinuria (~40%)
• Risk of pulmonary edema (21% of cases)

We recommend that all patients who develop mirror syndrome receive individualized counseling about delivery or abortion care; expectant management should be reserved only for rare circumstances after counseling about maternal risks 3.

Prognosis and Counseling

• Even after thorough evaluation, 15-25% of cases remain idiopathic 1, 2
• Earlier gestational age at diagnosis is associated with worse prognosis 4
• Overall survival beyond 28 days is approximately 9.2% in some series 5
• Idiopathic NIHF has a low recurrence risk, but some genetic causes carry up to 25% recurrence 1

Given the associated maternal risks and poor fetal prognosis, we recommend that all patients with pregnancies complicated by NIHF receive individualized counseling and be offered all management options, including abortion care 3.

When Etiology Remains Unknown

If comprehensive workup (ultrasound, MCA Doppler, genetic testing, infectious workup, lysosomal storage testing) fails to identify a cause:

• Consider exome/genome sequencing 3
• Ensure lysosomal storage disease testing was performed (often missed) 1
• Review for subtle structural anomalies that may have been overlooked
• Consider fetal MRI for additional anatomic detail
• Provide genetic counseling regarding recurrence risk

The key is systematic evaluation following the algorithm above, with particular attention to treatable causes (anemia, arrhythmias, infections) that can significantly improve outcomes when identified early.